JShamash

Professor Robert Horne and Dr Jonathan Shamash at @ucl and @NHSBartsHealth are investigating how Black men with advanced prostate cancer can be better supported to continue with cancer treatment.

GAMMA: Results from a phase II study for relapsed germ cell tumors using an oxaliplatin-based treatment regimen. ascopubs.org/doi/10.1200/JC…. Excited to present this multicentre trial on Saturday on behalf of @BartsECMC @daniel_berney @j_shamash and others! #GU22 #testicularca

meetinglibrary.asco.org/record/205706/… On behalf of the team, proud to present this Phase II trial abstract in #GU22. We report efficacy and toxicity data of an oxaliplatin-based regimen with high dose methotrexate in relapsed germ cell tumors. @urotoday @BartsECMC @BartsHospital @VJOncology

We are immensely proud to publish this pioneering piece from @NHSBartsHealth in @pcan_journal: the first European-based study to investigate impact of ethnicity on outcomes in metastatic castrate resistant PCa. nature.com/articles/s4139… 1/5 @urotoday @VJOncology @Diversityjobs4u

This is the story of our testis supraregional network: changes in centralised path and radiology diagnosis and eventual improvement in outcome over 10 years serving 7.5 million people. @BrJCancer #testis cancer doi.org/10.1038/s41416…

Our work at @BartsHospital published in @BJUIjournal today shows neutropenic fever admissions decrease by substituting high-dose #dexamethasone for olanzapine as antiemetic in BEP regimen. #QOL bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.11… @j_shamash @mdstbarts @StBartsTCGroup @TCSociety @TCancer

Despite higher incidence of prostate cancer in black men, outcomes the same if not better than white men in mCRPC - with indication of contribution to survival derived from hormone-based treatment @ProstateUK @ThePCRC @ProstateAwareFd

I'm thrilled to see these data . From a man who was instrumental in my career guidance and inspiration @ICR_CTSU

At #GU20 San Francisco. Our work from @BartsHospital, London across 20 yrs of data studying outcomes by ethnicity in mCRPC PCa has gained an ASCO Merit Award and selected for the Poster Walk highlight today. #BAME @j_shamash @barts_team @mdstbarts @barts_team @5aGhf @ProstateUK

#GU20 From 425 patients, Black pts with mCRPC don’t do worse than White men (HR 0.81, p=0.08). For the 106 patients who did not receive any chemo, Black pts did better (HR 0.54, p=0.019). Incidence may be higher in Black men, but outcomes are similar or better! @ProstateUK #BAME

The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis #VisualAbstract @robert_huddart @NPortaStat europeanurology.com/article/S0302-…

Very very honoured to have our prostate research win both best oral and poster presentation at #bug16. A testament to the collaborative work of the Urooncological teams at Barts, UCLH, and Barnet towards improving patient outcomes @shiv_smith @Michelle_Barts

Early bird closes 17th February Book your place nationalgermcellgroup.org.uk